Rabbit polyclonal anti-T-cell globulin used for in vivo T-cell depletion and immunosuppression.
Rabbit polyclonal anti‑thymocyte globulin that binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, adhesion/HLA molecules) and depletes T lymphocytes via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in potent in vivo T‑cell immunosuppression.
Thymoglobulin includes antibodies to adhesion molecules such as CD18; antibody binding to CD18+ cells activates complement and engages Fc receptor–bearing effectors, causing CDC/ADCC (and apoptosis) to deplete those cells.
Rabbit polyclonal anti-T-cell globulin used for in vivo T-cell depletion and immunosuppression.
Rabbit polyclonal anti‑thymocyte globulin that binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, adhesion/HLA molecules) and depletes T lymphocytes via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in potent in vivo T‑cell immunosuppression.
Thymoglobulin contains antibodies that bind HLA class I molecules on lymphocytes, triggering complement-dependent cytotoxicity and Fc-mediated ADCC, leading to lysis/apoptosis of target-expressing cells.
Rabbit polyclonal anti-T-cell globulin used for in vivo T-cell depletion and immunosuppression.
Rabbit polyclonal anti‑thymocyte globulin that binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, adhesion/HLA molecules) and depletes T lymphocytes via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in potent in vivo T‑cell immunosuppression.
Thymoglobulin contains antibodies that bind HLA-DR on cell surfaces and mediate complement-dependent cytotoxicity and Fc-dependent ADCC, and can induce apoptosis upon crosslinking, leading to depletion of HLA-DR–positive cells.
An intravenous glyco-humanized polyclonal antibody (biologic immunotherapy) engineered with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function; expected to mediate tumor cell killing via ADCC, ADCP, and CDC in advanced/metastatic solid tumors.
Glyco‑humanized polyclonal antibody that binds multiple tumor epitopes and is engineered with human-like Fc glycosylation to enhance Fc effector function and reduce immunogenic carbohydrates; kills tumor cells via Fc-dependent mechanisms including ADCC (via Fcγ receptor–bearing NK cells), ADCP (macrophages), and CDC (classical complement activation).
Antibody binds tumor-associated antigens and kills via Fc-dependent effector functions: ADCC by NK cells (FcγR), ADCP by macrophages, and complement-dependent cytotoxicity (CDC).
Anti-CD20 monoclonal antibody that depletes B cells via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with potential direct apoptotic effects, thereby reducing pathogenic B-cell activity.
Rituximab binds CD20 on B cells and its Fc engages immune effectors to trigger antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; CD20 crosslinking can also induce apoptosis.